These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 22981787)

  • 1. Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study.
    Patel D; Couroux P; Hickey P; Salapatek AM; Laidler P; Larché M; Hafner RP
    J Allergy Clin Immunol; 2013 Jan; 131(1):103-9.e1-7. PubMed ID: 22981787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fel d 1-derived synthetic peptide immuno-regulatory epitopes show a long-term treatment effect in cat allergic subjects.
    Couroux P; Patel D; Armstrong K; Larché M; Hafner RP
    Clin Exp Allergy; 2015 May; 45(5):974-981. PubMed ID: 25600085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cat peptide antigen desensitisation for treating cat allergic rhinoconjunctivitis.
    Worm M; Patel D; Creticos PS
    Expert Opin Investig Drugs; 2013 Oct; 22(10):1347-57. PubMed ID: 23964728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy of specific immunotherapy to cat dander: a double-blind placebo-controlled trial.
    Varney VA; Edwards J; Tabbah K; Brewster H; Mavroleon G; Frew AJ
    Clin Exp Allergy; 1997 Aug; 27(8):860-7. PubMed ID: 9291281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects.
    Alexander C; Tarzi M; Larché M; Kay AB
    Allergy; 2005 Oct; 60(10):1269-74. PubMed ID: 16134993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen.
    Patel P; Holdich T; Fischer von Weikersthal-Drachenberg KJ; Huber B
    J Allergy Clin Immunol; 2014 Jan; 133(1):121-9.e1-2. PubMed ID: 23870670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
    Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E
    Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
    Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
    Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of CRTh2 expression on allergen-specific T cells following peptide immunotherapy.
    Rudulier CD; Tonti E; James E; Kwok WW; Larché M
    Allergy; 2019 Nov; 74(11):2157-2166. PubMed ID: 31077596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
    Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
    J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.
    Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB
    Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis.
    Didier A; Worm M; Horak F; Sussman G; de Beaumont O; Le Gall M; Melac M; Malling HJ
    J Allergy Clin Immunol; 2011 Sep; 128(3):559-66. PubMed ID: 21802126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis.
    Didier A; Malling HJ; Worm M; Horak F; Sussman G; Melac M; Soulié S; Zeldin RK
    Clin Exp Allergy; 2013 May; 43(5):568-77. PubMed ID: 23600548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract.
    Nanda A; O'connor M; Anand M; Dreskin SC; Zhang L; Hines B; Lane D; Wheat W; Routes JM; Sawyer R; Rosenwasser LJ; Nelson HS
    J Allergy Clin Immunol; 2004 Dec; 114(6):1339-44. PubMed ID: 15577832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen.
    Skoner D; Gentile D; Bush R; Fasano MB; McLaughlin A; Esch RE
    J Allergy Clin Immunol; 2010 Mar; 125(3):660-6, 666.e1-666.e4. PubMed ID: 20153030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber.
    Nolte H; Maloney J; Nelson HS; Bernstein DI; Lu S; Li Z; Kaur A; Zieglmayer P; Zieglmayer R; Lemell P; Horak F
    J Allergy Clin Immunol; 2015 Jun; 135(6):1494-501.e6. PubMed ID: 25636947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of ragweed sublingual allergy immunotherapy tablets in adults with allergic rhinoconjunctivitis.
    Nayak AS; Atiee GJ; Dige E; Maloney J; Nolte H
    Allergy Asthma Proc; 2012; 33(5):404-10. PubMed ID: 23026182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of cat allergy with T-cell reactive peptides.
    Norman PS; Ohman JL; Long AA; Creticos PS; Gefter MA; Shaked Z; Wood RA; Eggleston PA; Hafner KB; Rao P; Lichtenstein LM; Jones NH; Nicodemus CF
    Am J Respir Crit Care Med; 1996 Dec; 154(6 Pt 1):1623-8. PubMed ID: 8970345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis.
    Frew AJ; Powell RJ; Corrigan CJ; Durham SR;
    J Allergy Clin Immunol; 2006 Feb; 117(2):319-25. PubMed ID: 16461133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, double-blind, placebo-controlled trial of standardized ragweed sublingual-liquid immunotherapy for allergic rhinoconjunctivitis.
    Creticos PS; Esch RE; Couroux P; Gentile D; D'Angelo P; Whitlow B; Alexander M; Coyne TC
    J Allergy Clin Immunol; 2014 Mar; 133(3):751-8. PubMed ID: 24332263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.